MASLD患者口服果糖后肝脏磷酸盐代谢的体内变化
本研究采用磷磁共振波谱(31P-MRS)比较伴或不伴MASLD的超重/肥胖非糖尿病患者口服75克果糖前后肝脏磷酸盐代谢物的体内变化。结果发现,无MASLD者果糖后磷酸单酯快速升高、无机磷酸盐先降后升、ATP显著下降;而MASLD患者这些反应均减弱。提示MASLD患者肝脏对果糖的代谢处理发生改变。
要点
- 无MASLD者口服果糖后15分钟内PME快速升高、ATP显著下降。
- MASLD患者上述磷酸盐代谢物反应减弱,仅45分钟时无机磷酸盐升高。
- MASLD患者肝脏对果糖的代谢处理存在差异,可能影响疾病进展。
核心结论
- MASLD患者口服果糖后肝脏磷酸盐代谢物变化模式与无MASLD者不同,提示肝脏果糖代谢处理改变。
研究设计与样本
- 37例无糖尿病的超重或肥胖患者接受2小时口服葡萄糖耐量试验、空腹肝脏质子磁共振波谱及口服75克果糖前后60分钟31P-MRS检查。
主要发现
- 果糖前两组ATP、PME和磷酸二酯无差异。
- 无MASLD者果糖后PME在15分钟内从15.5±4.8升至19.3±5.1(P=.033)。
- 无MASLD者无机磷酸盐前30分钟下降后升高,从10.2±1.9升至11.8±2.8(P=.037)。
- 无MASLD者ATP在15分钟内从21.8±3.4降至19.9±4.0(P=.018),60分钟后仍低于基线(19.1±4.1,P=.006)。
- MASLD患者PME不变,仅果糖后45分钟无机磷酸盐升高,ATP前15分钟非显著下降并于30分钟恢复基线。
临床怎么用
- 对于超重或肥胖的MASLD患者,需关注其肝脏对果糖的代谢反应差异可能影响疾病进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study compared in vivo changes in hepatic phosphate metabolites using phosphorus magnetic resonance spectroscopy (31P-MRS) in patients with vs without metabolic dysfunction-associated steatotic liver disease (MASLD) after oral fructose consumption. METHODS: Thirty-seven overweight or obese patients without diabetes underwent a 2-hour oral glucose tolerance test, a fasting liver proton magnetic resonance spectroscopy, and a 31P-MRS before and during 60 minutes after an oral 75-gram fructose challenge. RESULTS: Before fructose consumption, there were no differences in ATP, phosphomonoesters (PME), or phosphodiesters between groups. After fructose, patients without MASLD had a rapid increase in PME (from 15.5 ± 4.8 to 19.3 ± 5.1 within 15 minutes, P = .033). In these patients, inorganic phosphate (Pi) decreased during the first 30 minutes but then increased, leading to higher than baseline levels (from 10.2 ± 1.9 to 11.8 ± 2.8, P = .037). ATP significantly dropped in patients without MASLD within 15 minutes (from 21.8 ± 3.4 to 19.9 ± 4.0, P = .018), with persistently lower levels after 60 minutes (19.1 ± 4.1, P = .006 vs baseline). However, all these responses to oral fructose appeared blunted in patients with MASLD, with unchanged PME levels and only showing an Pi increase 45 minutes after fructose consumption. ATP levels showed a nonsignificant drop in the first 15 minutes with recovery of baseline levels at minute 30. CONCLUSION: Following fructose consumption, patients with MASLD exhibited distinct patterns of change in phosphate metabolites, reflecting differences in hepatic metabolic responses. These findings suggest altered hepatic metabolic handling of fructose in MASLD, which may have implications for disease progression.
引用
- Bril F, Forbes SC, Kalavalapalli S, et al. Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption. J Clin Endocrinol Metab. 2026. PMID: 41866318. doi:10.1210/clinem/dgag125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。